Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DAHF05
|
|||
| Drug Name |
TAK-101
|
|||
| Indication | Coeliac disease [ICD-11: DA95; ICD-10: K90.0; ICD-9: 579] | Phase 2 | [1] | |
| Company |
Takeda
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04530123) A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-101 for the Prevention of Gluten-Specific T Cell Activation in Subjects With Celiac Disease on a Gluten-Free Diet. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.